KMG Fiduciary Partners LLC Sells 4,785 Shares of Eli Lilly and Company $LLY

Key Points

• KMG Fiduciary Partners reduced its Eli Lilly stake by 16.3%, selling 4,785 shares and retaining 24,646 shares valued at approximately $29.6 million.
• Eli Lilly reported strong second-quarter results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38 versus the $6.40 consensus estimate. Management issued fiscal 2026 EPS guidance of $35.50 to $36.50.
• The stock traded near its 52-week high as analysts maintained a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $1,292.18. Lilly also received U.K. approval for its Foundayo obesity pill, strengthening its position in the growing GLP-1 market.

KMG Fiduciary Partners LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,646 shares of the company's stock after selling 4,785 shares during the quarter. Eli Lilly and Company accounts for approximately 2.7% of KMG Fiduciary Partners LLC's investment portfolio, making the stock its 10th biggest holding. KMG Fiduciary Partners LLC's holdings in Eli Lilly and Company were worth $29,561,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its stake in Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock valued at $33,471,000 after buying an additional 7,338 shares during the last quarter. Iams Wealth Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $754,000. Amundi grew its holdings in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after acquiring an additional 454,549 shares in the last quarter. May Hill Capital LLC grew its holdings in shares of Eli Lilly and Company by 131.6% in the fourth quarter. May Hill Capital LLC now owns 3,170 shares of the company's stock valued at $3,408,000 after acquiring an additional 1,801 shares in the last quarter. Finally, Caisse Des Depots ET Consignations increased its position in shares of Eli Lilly and Company by 17.3% during the fourth quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company's stock valued at $11,643,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

Eli Lilly and Company Trading Up 3.7%

NYSE:LLY opened at $1,230.00 on Tuesday. Eli Lilly and Company has a 1 year low of $625.90 and a 1 year high of $1,249.45. The stock's fifty day moving average price is $1,162.38 and its two-hundred day moving average price is $1,048.95. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market cap of $1.16 trillion, a P/E ratio of 41.28, a P/E/G ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 36.77 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LLY shares. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Finally, Citigroup increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source